Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease

Hye Yun Park, Andrew Churg, James R. Wright, Yuexin Li, Sheena Tam, S. F. Paul Man, Donald P. Tashkin, Robert A. Wise, John E. Connett, Don D. SinAmerican 2013 · DOI

TL;DR

This study investigates whether serum levels of Club Cell Protein 16 (CC-16), a lung-specific protein, can predict the progression of Chronic Obstructive Pulmonary Disease (COPD). The research found that lower CC-16 levels are associated with a faster decline in lung function over time, suggesting its potential as a biomarker for identifying "rapid progressors" in COPD. However, experiments in CC-16 deficient mice did not show a significant difference in smoke-induced lung damage, indicating CC-16's role in disease pathogenesis might be more nuanced.

What Problem Does This Paper Address?

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by a decline in lung function. A major challenge in COPD research and treatment is the heterogeneity of disease progression; some individuals experience a rapid decline in lung function, while others progress more slowly. Currently, there's a lack of reliable biomarkers that can accurately identify these "rapid progressors" early on. This makes it difficult to recruit suitable participants for clinical trials aimed at slowing disease progression and to develop targeted therapies. The study aims to explore whether serum CC-16, a protein primarily produced in the lungs and known to decrease with lung injury and smoking, could serve as such a predictive biomarker for COPD progression.

Methods

The study employed a two-pronged approach:

  • Human Study: Researchers analyzed data from the Lung Health Study (LHS), a large cohort of individuals with mild-to-moderate airflow limitation. They measured serum CC-16 levels in 4,724 participants at Year 5 of the study and used linear regression models to assess the relationship between these levels and the decline in lung function (specifically FEV1, forced expiratory volume in 1 second) over a 9-year period. They also adjusted for various confounding factors like age, sex, race, smoking status, body mass index, and airway reactivity. To evaluate CC-16's predictive power for rapid lung function decline, they constructed Receiver Operating Characteristic (ROC) curves.
  • Animal Study: To investigate the role of CC-16 in the development of COPD, the researchers used CC-16-deficient mice (CC-16-/-) and wild-type mice. These mice were exposed to cigarette smoke for six months. Following exposure, lung morphology was analyzed to assess emphysema (mean airspace size) and small airway remodeling (wall thickness and area). Inflammatory cell infiltration (macrophages and neutrophils) was also quantified.

Datasets

  • Lung Health Study (LHS) Cohort: This dataset comprises data from 4,724 participants with mild-to-moderate airflow limitation, including spirometry measurements over several years, smoking status, and serum CC-16 levels collected at Year 5.

Key Insights and Ideas

  • CC-16 as a Predictive Biomarker: The most significant finding is the inverse relationship between serum CC-16 levels and the rate of FEV1 decline. Lower CC-16 levels are associated with a faster loss of lung function, suggesting CC-16's potential as a biomarker for identifying individuals at risk of rapid COPD progression.
  • Enriching Clinical Trials: By identifying "rapid progressors" using CC-16 in conjunction with other clinical factors, researchers could potentially enrich future COPD clinical trial cohorts, leading to more precise and powerful studies.
  • Limited Role in Early Pathogenesis (in mice): Despite its association with disease progression in humans, CC-16 deficiency in mice did not lead to increased susceptibility to emphysema or small airway remodeling after chronic smoke exposure. This suggests that CC-16 might not play a critical role in the early stages of smoke-induced lung damage, or its protective mechanisms are more complex.
  • Intermittent Quitters as a Key Group: The study noted that the correlation between CC-16 and FEV1 decline was particularly significant in intermittent smokers, though this finding should be interpreted with caution due to multiple comparisons.

Key Results

  • Reduced serum CC-16 concentrations were significantly associated with accelerated FEV1 decline over 9 years (P < 0.0001), even after adjusting for multiple confounding factors (P = 0.0002).
  • The addition of serum CC-16 to a model of clinical risk factors (smoking status, airway reactivity, baseline FEV1, sex, age, BMI, and race) significantly increased the area under the curve (AUC) for predicting rapid FEV1 decline (≥40 ml/yr) from 0.66 to 0.67 (P = 0.0335).
  • A CC-16 cutoff value of 3.5 ng/ml was independently associated with rapid FEV1 decline (odds ratio = 1.358; P = 0.0001).
  • In the animal study, CC-16-/- mice did not show enhanced risk of emphysema or small airway remodeling in response to cigarette smoke compared to wild-type mice.
  • Inflammatory cell counts (macrophages and neutrophils) were generally increased by smoke exposure in both wild-type and CC-16-/- mice, with no significant differences between the genotypes.

Limitations and Future Work

The authors acknowledge several limitations:

  • Mild-to-Moderate COPD Cohort: The study primarily used data from the Lung Health Study, which included participants with mild-to-moderate COPD. Therefore, the findings may not be directly applicable to patients with more severe disease.
  • Lack of CT Phenotyping: The LHS cohort did not include thoracic computed tomography (CT) scans, which could have provided information on emphysema extent and other morphological phenotypes. This limits the ability to correlate CC-16 with specific structural changes.
  • No Serial CC-16 Measurements: The study did not have serial measurements of CC-16, preventing an analysis of intraindividual variation over time.
  • Modest Effect Size: While statistically significant, the overall strength of the association between CC-16 and FEV1 decline was relatively small, suggesting CC-16 may not be a standalone biomarker but rather a component of a multi-biomarker panel.
  • Animal Model Limitations: The animal study was relatively small, and it's possible that subtle differences in pathological processes related to cigarette smoking between CC-16-/- and wild-type mice were missed. The authors suggest that larger investigations are needed to clarify CC-16's role in COPD pathogenesis, especially in more advanced stages that may not be fully modeled in mice.

Future work should focus on validating these findings in larger, more diverse COPD cohorts, including those with severe disease. Further research is also needed to explore the precise mechanisms by which CC-16 influences COPD progression and to investigate its potential modifiability by therapeutic interventions. Combining CC-16 with other biomarkers and clinical factors could lead to more robust predictive models for COPD progression.

Summary updated

Abstract

Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigarette-related COPD in mice.
BibTeX
@inproceedings{park2013club,
  author = {Hye Yun Park and Andrew Churg and James R. Wright and Yuexin Li and Sheena Tam and S. F. Paul Man and Donald P. Tashkin and Robert A. Wise and John E. Connett and Don D. Sin},
  title = {{Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease}},
  booktitle = {American},
  year = {2013},
  doi = {10.1164/rccm.201305-0892oc},
}
Figure